<div id="readability-page-1"><div><ul> <li>The Chemours Company recently announced that Michael Foley will become President of Chemours Titanium Technologies in February 2026, bringing experience leading a US$1.00 billion specialty chemicals portfolio at Momentive Performance Materials. </li> <li>Foley’s background in portfolio optimization, organizational restructuring, and Lean and Six Sigma practices signals a potential shift in how Chemours manages efficiency and profitability in its core titanium dioxide segment.</li> <li>Now we’ll examine how Foley’s appointment to lead Titanium Technologies may influence Chemours’ existing investment narrative and risk-reward profile.</li> </ul><p>AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</p><h2>Chemours Investment Narrative Recap</h2><p>To own Chemours today, you need to believe that its core titanium dioxide and fluorochemicals businesses can convert operational improvements into durable cash generation despite ongoing losses and PFAS overhangs. Foley’s appointment to lead Titanium Technologies is a longer-dated development and does not materially change the near term focus on stabilizing earnings and managing litigation and regulatory risk.</p> <p>Recent analyst actions, including JP Morgan’s Neutral rating and reduced US$13.00 price target, frame Foley’s hire against a backdrop of tempered expectations and a Hold-leaning consensus. That context matters as investors weigh potential efficiency gains in Titanium Technologies against persistent concerns around legal liabilities, regulatory costs, and cyclical TiO₂ demand.</p> <p>Yet while leadership change may support long term execution, investors should be aware of how unresolved PFAS litigation could still...</p> <p>Read the full narrative on Chemours (it's free!)</p><p>Chemours' narrative projects $6.6 billion revenue and $671.0 million earnings by 2028.</p><p>Uncover how Chemours' forecasts yield a $17.78 fair value, a 40% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4682c520-c03c-4071-bd6c-fe7b67208b11/chart/community-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4682c520-c03c-4071-bd6c-fe7b67208b11/chart/community-fair-value"/><figcaption>CC Community Fair Values as at Dec 2025</figcaption></figure> <p>Five fair value estimates from the Simply Wall St Community span roughly US$11.55 to US$26.59, underlining how far apart individual views can be. You may want to compare those opinions with the risk that unresolved PFAS and environmental liabilities could pressure Chemours’ cash flows and influence how the market values any operational progress in Titanium Technologies.</p><p>Explore 5 other fair value estimates on Chemours - why the stock might be worth 9% less than the current price!</p><h2>Build Your Own Chemours Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Chemours research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.</li><li>Our free Chemours research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemours' overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Chemours appoints Michael Foley as President of Titanium Technologies, effective February 2026. Foley's expertise in portfolio optimization and Lean practices may enhance efficiency in Chemours' titanium dioxide segment. Analysts remain cautious, with JP Morgan maintaining a Neutral rating and a reduced price target of $13.00. Investors should consider Foley's long-term impact against ongoing PFAS litigation and regulatory risks. Chemours projects $6.6 billion revenue and $671 million earnings by 2028, with a fair value estimate of $17.78, offering a 40% upside.</p>

How Investors Are Reacting To Chemours (CC) Appointing Michael Foley To Lead Titanium Technologies